Viasys Orion CPAP
This article was originally published in The Gray Sheet
Executive Summary
Obstructive sleep apnea therapy device is launched May 30 via SensorMedics unit's 22 sales reps following 510(k) clearance, announced May 28. The $250 Orion's unique features include quiet performance, altitude and patient compliance meters, and a range of color and other appearance options expected to increase patient compliance. Separately, Viasys announces May 23 that its Avea ventilator will begin shipping by October following the recent 510(k) clearance for neonatal, pediatric and adult patients...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.